59 research outputs found

    Thoracic Operations for Pulmonary Nodules Are Frequently Not Futile in Patients with Benign Disease

    Get PDF
    IntroductionPulmonary nodules often require operative resection to obtain a diagnosis. However, 10 to 30% of operations result in a benign diagnosis. Our purpose was to determine whether negative thoracic operations are futile by describing the pathological diagnoses; determining new diagnoses and treatment changes initiated based on operative findings; and assessing morbidity, mortality, and cost of the procedure.MethodsAt our academic medical center, 278 thoracic operations were performed for known or suspected cancer between January 1, 2005, and April 1, 2009. We collected and summarized data pertaining to preoperative patient and nodule characteristics, pathologic diagnosis, postoperative treatment changes resulting from surgical resection, perioperative morbidity and mortality, and hospital charges for patients with benign pathology.ResultsTwenty-three percent (65/278) of patients who underwent surgical resection for a suspicious nodule had benign pathology. We report granulomatous disease in 57%, benign tumors in 15%, fibrosis in 12%, and autoimmune and vascular diseases in 9%. Definitive diagnosis or treatment changes occurred in 85% of cases. Surgical intervention led to a new diagnosis in 69%, treatment course changes in 68% of benign cases, medication changes in 38%, new consultation in 31%, definitive treatment in 9%, and underlying disease management in 34%. There was no intraoperative, in-hospital, or 30-day mortality. Postoperative in-hospital events occurred in seven patients. The mean total cost was 25,515withameancostperdayof25,515 with a mean cost per day of 7618.ConclusionsPatients with a benign diagnosis after surgical resection for a pulmonary nodule received a new diagnosis or had a treatment course change in 85% of the cases

    Therapeutic efficacy of intra-articular delivery of encapsulated human mesenchymal stem cells on early stage osteoarthritis

    Get PDF
    Mesenchymal stem cells (MSCs) represent a great therapeutic promise in pre-clinical models of osteoarthritis (OA), but many questions remain as to their therapeutic mechanism of action: engraftment versus paracrine action. Encapsulation of human MSCs (hMSCs) in sodium alginate microspheres allowed for the paracrine signaling properties of these cells to be isolated and studied independently of direct cellular engraftment. The objective of the present study was to quantitatively assess the efficacy of encapsulated hMSCs as a disease-modifying therapeutic for OA, using a medial meniscal tear (MMT) rat model. It was hypothesized that encapsulated hMSCs would have a therapeutic effect, through paracrine-mediated action, on early OA development. Lewis rats underwent MMT surgery to induce OA. 1 d post-surgery, rats received intra-articular injections of encapsulated hMSCs or controls (i.e., saline, empty capsules, non-encapsulated hMSCs). Microstructural changes in the knee joint were quantified using equilibrium partitioning of a ionic contrast agent based micro-computed tomography (EPIC-μCT) at 3 weeks post-surgery, an established time point for early OA. Encapsulated hMSCs significantly attenuated MMT-induced increases in articular cartilage swelling and surface roughness and augmented cartilaginous and mineralized osteophyte volumes. Cellular encapsulation allowed to isolate the hMSC paracrine signaling effects and demonstrated that hMSCs could exert a chondroprotective therapeutic role on early stage OA through paracrine signaling alone. In addition to this chondroprotective role, encapsulated hMSCs augmented the compensatory increases in osteophyte formation. The latter should be taken into strong consideration as many clinical trials using MSCs for OA are currently ongoing

    Research Progress Reports: Fruit and Vegetable Processing and Technology Division, Department of Horticulture [1967]

    Get PDF
    Evaluation of snap bean varieties for processing / Wilbur A. Gould and William Hildebolt -- Evaluation of various grape cultivars for processing. I. Table wines ; Recommended fruit varieties for canning and freezing / J. F. Gallander -- Evaluation of tomato varieties for processing / W. A. Gould, J. R. Geisman, C. S. Parrott, J. H. McClelland and W. N. Brown -- The effect of different levels of sugar and acid on the quality of apple fruit juice blends / James Gallander and Harold Stammer -- Epidermal sloughing of snap beans as influenced by processing variables / William Hildebolt and W. A. Gould -- Effect of stannous chloride on the color of glass packed kraut / J. R. Geisman -- Proteins and enzymes in the apple fruit in relation to variety and maturation ; Proteins and enzymes in tomato fruits / Robert L. Clements -- Effect of food additives on quality of canned tomatoes / Wilbur A. Gould -- Effects of selective herbicides on the composition and quality of tomatoes / W. A. Gould, J. R. Geisman, E. K. Alban and John Deppen -- Trace levels of pesticide residues in agricultural commodities in marketing channels / W. A. Gould, J. R. Geisman, E. K. Alban, John Deppen, and P. van Pottlesberghe -- Removal of DDT residues by unit operations in preparing and processing spinach / J. R. Geisman, John Deppen and Benita Yao -- The use of chlorine dioxide in handling and holding mechanically harvested tomatoes / J. R. Geisman, Winston D. Bash, Edwin Schmidt, Jr., Linda Hamrick and W. A. Gould -- Effect of mechanical harvesting and handling of tomatoes on quality of canned tomatoes / Wilbur A. Gould, J. R. Geisman, Edwin Schmidt, Jr., John McClelland and W. N. Brow

    Evidence-based PET for thoracic tumours

    Get PDF
    AbstractFluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is a robust imaging tool that is currently used in daily clinical practice for the evaluation of thoracic malignancies. This chapter provides an overview of the current evidence-based data on the usefulness of PET/CT for the evaluation of patients with thoracic tumours including lung cancer, pleural and thymic tumours, and esophageal cancer
    corecore